9:30 Registration and welcome coffee
10:00 Welcome from hosts
10:10 Session 1
11:40 Lunch & Networking
12:30 Session 2
14:00 Pre-arranged meetings (Coffee and Networking for anyone wanting to stay)
15:00 Closing
Free registration subjected to organizer’s validation.
The Nordics and Medicon Valley feature world-class healthcare and research institutions, highly skilled hardware and software expertise, a thriving game industry and a strong startup scene. When Nordic Life Science Days (NLSDays) is coming to Malmö 10th – 12th of September this year, this is a unique opportunity to showcase regional life science strongholds and reach out to the many international stakeholders that are here.
In order to seize this opportunity, Medicon Valley Alliance (MVA), Invest in Skåne, Copenhagen Capacity, and Medicon Valley Medtech Network have joined forces and decided to bring regional Danish and Swedish Health Tech expertise and entrepreneurship together with the international life science community of industry experts, investors and academia. Join us and be part of creating tomorrow’s HealthTech solutions by connecting international Health Tech stakeholders with start-ups and researchers to address challenges in health care!
Medicon Valley Alliance, Copenhagen Capacity, and Invest in Skåne are happy to invite you to NLSDays Side Event – Health Tech
1. Read about and sign up for the VIP event here.
2. After signing up, if you would like to apply to do a pitch for the challenges please send an email with your application to Business Development Manager Fredrik.Lindqvist@skane.se no later than 14th August.
NLSDays is a fantastic meeting for finding the knowledge and contacts to develop your gene and cell therapy research into medicinal products.
As an ease in to NLSDays in Malmö, Swelife-ATMP, Bioneer, Medicon Village and CAMP are hosting a supporting event to start to discuss the issues around ATMP product development and commercialisation of gene and cell therapy research. You will also get the opportunity to network with other academics and businesses ATMPs.
We welcome you to this event free of charge and encourage you to register for NLSdays 2019 which will also host an event on Phase I to reimubursement support of ATMP technologies. We encourage you also to check out the partnering options for NLSdays, the right contacts are going to be essential in bringing your therapy to patients.
Would you like to get to know Galenica AB a little bit better? Please visit us for a presentation of the company followed by a site tour of our facilities. Numbers are limited.
Shuttle from Malmömässan at 12:45 in front of the Conference Center.
Shuttle back from Galenica to Malmömässan.
MODERATOR:
Dr. Sara Gunnerås – Director Business & Finance, SwedenBIO
SPEAKERS:
Dr. Peter Lindberg – National Project Officer EUREKA, Vinnova
Dr. Jonas Tranell – Eurostars Project Officer, Health Department, Vinnova
Mr. Mael Mbaye – Project Officer, Bpifrance
Mr. Martin Waleij – CEO BrainCool AB
Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises. With its bottom-up approach, Eurostars is an ideal first step in international cooperation, enabling small businesses to combine and share expertise and benefit from working beyond national borders. The role of SMEs for the economy has never been so important. Eurostars aims to bring increased value to the economy, higher growth and more job opportunities.
On the Agenda
Hosted by:
Spark Norway
Spark Finland
SciLifeLab
BioInnovation Institute
UiO: University of Oslo
Oslo Cancer Cluster
The Life Science Cluster
Health Turku
Promote Iceland
Sponsored by:
Arthur D. Little
EIT Health
This year we inaugurate the new Nordic Life Science Awards competition.
The Nordic Life Science Awards will be given to one academic research group project (“Academic Class”) with a break-through potential and to one life science-company (“Business Class”) with products or projects that can contribute to great patient benefit. A second company (“Delegates Choice”) will be selected by popular vote onsite.
The Jury consists of:
Part 1 – Nordic Life Science Academic Class Award
| “Advancing academic ideas into innovations for patients”
Academia is a key engine for medical innovation and many life science projects becoming commercial successful originate from academic centers. Big ideas very often come from ground-braking academic research. Recognizing that the majority of the global companies made academic-industrial partnerships an integral part of their strategies and opened their R&D organizations to external innovation. The Nordic Life Science Awards – Academic Class presentations features exciting academic projects from five Nordic countries illustrating the rich and broad research milieus and their motivation to advance their ideas into innovations for patients. The session is hosted by SPARK Norway and delivered in collaboration with SPARK Finland, the Swedish SciLifeLabs, the Danish BioInnovation Institute, Promote Iceland and sponsored by Arthur D. Little and EIT Health Scandinavia. |
SciLifeLab Sweden
|
SPARK Norway, UiO:Life Science at the University of Oslo
|
SPARK Finland
|
BioInnovation Institute Denmark
|
Iceland
|
Part 2 – Nordic Life Science Business Class and Delegates Choice Awards
Nordic life science companies are well known and respected for their strong science-base and a long history of bringing innovation to the market. The company session will feature two companies from each of the Nordic countries. The winner of the “Business Class Award” show scientific excellence and run projects that have a break-through possibility or have already made it to the market adding significant value to patients. For the “Delegates Choice Award”: the audience will be asked to vote for the company they are most likely to invest in should they be given the opportunity. The session is hosted by SwedenBIO, Oslo Cancer Cluster, Turku Science Park, the Danish BioInnovation Institute and sponsored by Arthur D. Little and EIT Health Scandinavia.
Moderator:
Ms. Sarah Lidé, Senior strategy and project manager, Medicon Valley Alliance
Finalists:
Aiforia Technologies (Finland) Deep learning AI for image analysis
Akthelia (Iceland) A novel antimicrobial platform
Cirqle Biotechnologies (Denmark) Focused on developing innovative contraceptives
Delsitech (Finland) New nanotech solutions in drug delivery
Elypta (Sweden) Metabolic biomarkers and AI to detect cancer
EpiEndo (Iceland) Focused on novel solutions for chronic airway diseases
Kongsberg Beam Technology (Norway) Precision against cancer
SARomics Biostructures (Sweden) Protein crystallography and drug discovery services
Synklino (Denmark) Eradicating cytomegalovirus infections
Vaccibody (Norway) Tailored vaccine therapy
The opening plenary welcomes you all and marks the beginning of the 7thNordic Life Science Days! Get inspired and listen to our highly ambitions Nordic life science agenda.
Moderator(s): Ms. Helena Strigård - Deputy Director General, SwedenBIO
Speaker(s):
Mr. Olivier Duchamp - Managing Director, NLSDays - VP International BD & Promotion, SwedenBIO
Ms. Ann Linde - Swedish Minister for Foreign Trade, with responsibility for Nordic affairs
Mr. Hans Erik Henriksen - CEO, HealthCare Denmark
Mr. Peter Albiez - Country Manager, Pfizer Germany
Dr. Lotta Ljungqvist - President & CEO GE Nordics & CEO Testa Center at GE Healthcare
Mr. Terje Straume - Global Head HealthCare, DNB Bank
Measured by the high level of business activities and the impressive number of companies, the Nordic life science sector is strong in an international context and has contributed to many innovations on the global market. Appropriate and timely financing is a must for the Nordic life science companies in order to progress the development of their respective project pipelines. This session highlights specific Nordic features such as the growing number of early to mid-stage companies listed at the stock exchanges and discuss how to maintain a sustainable life science capital market in the Nordics.
Part 1: From seed to IPO: the stages of StartUp fundraising
Part 2: Stockholm, the capital of IPOs (IPOs as exit possibility for VCs)
Part 3: Maintaining a sustainable life science capital market in the Nordics
Moderator(s): Dr. Sonja Benhamida - Senior Vice President Healthcare, DNB
Speaker(s):
Dr. Thomas Grotkjaer - Principal, Novo Holdings
Mr. Thomas Gidlund - Investment Manager, Sciety
Mr. Ari-Pekka Laitsaari - Growth Capital and Innovation Finance, European Investment Bank
Mr. Shutian Liu - Managing Partner and Founding Partner, Button Capital
Mr. Adam Kostyal - Senior Vice President, Nasdaq OMX
Mr. Patrik Ling - Senior Analyst HealthCare, DNB Markets
Dr. Patrick Sobocki - Investment Manager, Industrifonden
10:45 Ferring Pharmaceuticals - Pharmaceutical 11:00 Johnson & Johnson Innovation - Pharmaceutical 11:15 MSD - Pharmaceutical 11:30 Pfizer - Pharmaceutical 11:45 Sanofi - Pharmaceutical 12:00 Amgen - Pharmaceutical
CNS diseases continue to pose immense burdens on both patients and society as a whole. But despite enormous amount of research most of current treatments only temporarily improve symptoms. What is needed to accelerate the development? Who is willing to invest in the neuroscience development projects despite all setbacks? And can we expect breakthroughs the coming years that will change the way we will address the neurosciences area? International experts will share their views on what is expected and possible based on currently available knowledge.
Moderator(s): Ms. Ingrid Heath - Partner, Adlersson & Heath
Speaker(s):
Dr. Jina Elise Swartz - Global Clinical Development, MSD
Dr. Per-Ola Freskgård - Vice Director & Distinguished Scientist Neuroscience, pRED Roche Innovation Center
Dr. Roman Lassnig - Development Engineer, Printed Electronics, Biocom Lab/RISE
Dr. Patrick Sobocki - Investment Manager, Industrifonden
Dr. Steffen Thirstrup - Director, NDA Regulatory Advisory Board
14:00 Annexin Pharmaceuticals - Biotechnology - Therapeutics & Diagnostics 14:13 Aqilion - Biotechnology - Therapeutics & Diagnostics 14:26 Beactica - Biotechnology - Therapeutics & Diagnostics 14:39 CanImGuide Therapeutics - Biotechnology - Therapeutics & Diagnostics 14:52 Gedea Biotech - Biotechnology - Therapeutics & Diagnostics 15:05 Immunicum - Biotechnology - Therapeutics & Diagnostics 15:18 DelSiTech - Pharmaceutical 15:31 Scandinavian Biopharma - Biotechnology - R&D Services
During the last 30 years outsourcing has changed from the rare occurrence to become a strategic board question how to speed up and de-risk development of the company’s projects. For small and large companies alike, no one researches, develops or produces solely on their own. The industry once outsourced the overflow activities; it has now turned into a specialized industry with their own research and methods development to serve their clients in this highly competitive market.
In this interactive session (you will have a green and red sign to vote), we will listen to some good examples of how outsourcing could be done, where we all win.
Moderator(s): Mr. Sverre Bengtsson - Co-Founder, Owner and Senior VP Strategic Relations, PCG Solutions / Viedoc
Speaker(s):
Dr. Eric Meldrum - CSO, ENYO Pharma
Mr. Antonio Iervolino - Associate Principal, IQVIA
Dr. Peter Gaskin - Senior Director, Scientific Advisory Services, Charles River Laboratories
Dr. John Montana - Corporate VP, Integrated Drug Discovery & Strategic Projects, Charles River Laboratories
Moderator(s): Dr. Christina Östberg Lloyd - Clinical Medical Regulatory Director, Novo Nordisk & Chairman, Swelife
Speaker(s):
Prof. Malin Parmar - Associate Professor, Lund University
Mr. Leo Groenewegen - Business Developer, NextCell Pharma
Dr. Carlos De Sousa - CEO, Immunicum
Dr. Christoph Varenhorst - Medical Director, Pfizer
Dr. Cecilia Ahlin - Medical Head Oncology, Novartis Sweden
Dr. Björn Odlander - Managing Partner, HealthCap
Mr. Daniel Bolanowski - Senior Analyst, Arctic Fund Management
15:45 EY - Professional Services & Consulting 16:01 EIT Health Scandinavia - Public & Non-Profit Organizations 16:14 S-cubed - CRO/CMO/CDMO 16:21 S-cubed - CRO/CMO/CDMO 16:28 Venn Life Sciences - Professional Services & Consulting 16:35 GEA – Continuous solid dosage technologies - Supplier & Engineering
Welcome to an interactive session on Innovative Medicines Initiative (IMI), an EU public-private partnership funding health research and innovation. This is the opportunity for you as an SME, patient organisation, healthcare industry or academia representative or any other key healthcare player, to learn more about how to engage with IMI, upcoming calls, get a SME testimonial and – most of all- a chance to get your questions answered !
Moderator(s): Ms. Caroline Ekstrand - Program Manager, Vinnova
Speaker(s):
Mr. Nicolas Creff - Senior Manager, Research Partnerships and Science Policy and Regulatory Affairs, EFPIA
Ms. Magali Poinot - Advisor to Executive Director, IMI Executive Office
Dr. Karin von Wachenfeldt - CEO, Truly Labs
Dr. Gunnar Sandberg - Chair of IMI State Representative Group and Program Manager, Vinnova
Dr. Elisabet Nielsen - Program Manager, Vinnova
Many ground-breaking life science innovations have their origin in the Nordics. Why is that? Can we utilize our developed ability to collaborate and exchange experiences to increase return on investment and develop our businesses further? In this thought-provoking and educational session, we will have a look at the Nordic life science innovation landscape. We will discuss different forms of collaborations forming a fostering environment for innovation. You’ll get a taste of exciting open innovation opportunities at LEO Pharma, and learn how RISE, the Research Institutes of Sweden, collaborate with Pfizer around new therapies. Also, find out where Nordic projects can reach global dimensions in collaboration with the US National Institutes of Health. A crucial part is of course how to do business of the collaboration, which will be a theme throughout our session.
Moderator(s): Ms. Louise Jonshammar - Attorney At Law, AWA
Speaker(s):
Dr. Niclas Nilsson - Head of Open Innovation in Research, LEO Pharma
Dr. Magnus Larsson - Vice President, Head of Unit Surface - Process and Formulation, RISE
Dr. Ann-Charlotte Dorange - Health & Value Lead (Health Economics/HTA), Pfizer
Dr. Michael L. Salgaller - Supervisor, Invention Development and Marketing Unit (IDMU), National Institutes of Health
17:15 Charles River USA - CRO/CMO/CDMO 17:31 Cobra Biologics - CRO/CMO/CDMO 17:44 Recipharm - CRO/CMO/CDMO 17:57 Coriolis Pharma - CRO/CMO/CDMO 18:10 Mercodia - Supplier & Engineering
An outstanding location overlooking the Øresund bridge combining the raw nature in the best way with a futuristic expression in architecture.
Shuttle busses will depart from MalmöMässan main entrance from 18:30 until 19:30
Shuttle busses will depart from Luftkastellet from 21:00 until 22:30 to Malmömässan and main hotels downtown Malmö.
Digitalization is becoming an increasingly important part of healthcare, life sciences and clinical trials. Stakeholders from these areas are contributing to this development in different ways. The session will present various perspectives of how diabetes patients can benefit from such digital revolution.
Moderator(s): Dr. Gaspar Taroncher-Oldenburg - Editor-at-Large, Nature Publishing Group
Speaker(s):
Dr. Michel de Baar - Executive Director, BD&L - Infectious Diseases, Vaccines, Cardiometabolic, Immunology & Inflammation, MSD
Dr. Lars Gustafsson - Expert, Healthcare Digitalization - CGI/KI
Mr. Thomas Magnusson - Chairman of the Board, The Diabetes Organisation of Sweden
Dr. Damon Tojjar - Managing Director, Easy Diabetes
Dr. Rob Harris - Director Science and Technology, Catalent Pharma Solutions
08:45 Sirion Biotech - Biotechnology - Other 08:52 Vicore Pharma - Biotechnology - R&D Services 09:05 ENYO Pharma - Biotechnology - Therapeutics & Diagnostics 09:18 AstraZeneca - Pharmaceutical 09:34 Bristol-Myers Squibb - Pharmaceutical 09:50 Boehringer Ingelheim - Pharmaceutical 10:06 RhoVac - Biotechnology - Therapeutics & Diagnostics
The global oncology pipeline is growing at an unprecedented rate, the number of approved therapies continues to rise and advances in cancer immunotherapy, novel cell and gene therapies offer novel therapeutic options. At the same time, big data, AI and digital solutions are changing drug development, diagnostics and patient care. In this forward-looking session international experts will highlight recent advances and illustrate these with case studies and examples. They will share their perspectives on how precise and personalized today’s approaches really are and how different technologies and new collaborations can address existing challenges and limitations.
Moderator(s): Dr. Gaspar Taroncher-Oldenburg - Editor-at-Large, Nature Publishing Group
Speaker(s):
Dr. Mark Swindells - Chief Operating Officer, Exscientia
Ms. Kaisa Helminen - CEO, Aiforia Technologies
Dr. Jørn Skibsted Jakobsen - Vice President, Global Clinical Research and Development, Ferring Pharmaceuticals
Mr. Marko Kuisma - Chief Commercial Officer, Kaiku Health
Prof. Carl Borrebaeck - Professor, Lund University
Prof. Kristian Pietras - Professor of Molecular Medicine, Lund University
Dr. George Coukos - Director Department of Oncology, University of Lausanne
10:40 Invest Stockholm - Public & Non-Profit Organizations 10:45 Cartana - Biotechnology - R&D Services 10:52 Abera Bioscience - Biotechnology - Therapeutics & Diagnostics 10:59 Sprint Bioscience - Biotechnology - Therapeutics & Diagnostics 11:06 NextCell Pharma - Biotechnology - Therapeutics & Diagnostics 11:13 Sigrid Therapeutics - Biotechnology - Therapeutics & Diagnostics 11:20 Sinfonia Biotherapeutics - Biotechnology - Therapeutics & Diagnostics 11:27 Pelago Bioscience - Biotechnology - Therapeutics & Diagnostics 11:34 Ilya Pharma - Pharmaceutical 11:41 RISE-Research Institutes of Sweden - Public & Non-Profit Organization 11:48 RISE-Research Institutes of Sweden - Public & Non-Profit Organization 11:55 S-cubed - CRO/CMO/CDMO 12:02 Immuneed - CRO/CMO/CDMO 12:09 LGC Group - CRO/CMO/CDMO 12:16 Particle Analytical - CRO/CMO/CDMO
We are currently going through an unprecedented era of scientific, medical and technological innovation. The shift from a one-size-fits-all model to more targeted and individualized care has a suite of implications for all players across the healthcare life science ecosystem; forcing payers, providers, and drug and device manufacturers to rethink their business, operating, and collaboration models. This session will discuss how Nordic ecosystem players need to mobilize and how to take advantage of strongholds in the Nordic countries to take a globally leading position when cross-functional collaboration will be a necessity and key competences will be a scarcity.
Moderator(s): Dr. Ulrica Sehlstedt - Partner, Arthur D. Little
Speaker(s):
Dr. Thomas Unger - Associate Director, Arthur D. Little
Dr. Magnus R. Björsne - CEO, AZ BioVentureHub
Dr. Annette Bak - Senior Director – Head of Advanced Drug Delivery, AstraZeneca
MAX IV and ESS, DESY and European XFEL position Northern Europe as a globally unique region for Life Science Innovation and Research. Get inspiration on how to develop your products and stay competitive within your area. The session will include an interactive panel discussion and take off from the newly started EU project ‘Hanseatic League of Science (HALOS)’, www.halos.lu.se
Moderator(s): Assoc. Prof. Kajsa Paulsson - Session's Chairman, Associate Professor, Lund University Dr. Anna Stenstam - CEO, CR Competence
Speaker(s):
Prof. Erik Renström - Professor, Lund University
Mr. Fredrik Melander - Head of R&D Relations, Science Village Scandinavia
Dr. Selma Maric - Coordinator Industrial Relation, Life Sciences, MAX IV
Dr. Uwe Sassenberg - Head EU-Projects, Innovation and Technology Transfer, DESY
Assoc. Prof. Tomas Lundqvist - Coordinator for Large Scale Research Infrastructures, RISE
Dr. Anna Sandström - Science Policy and Relations Director Europe, AstraZeneca
Prof. Lene Oddershede - Head of grants for research, Novo Nordisk Foundation
Dr. Jonas Fransson - Director, SOBI (Swedish Orphan Biovitrum)
Dr. Niclas Nilsson - Head of Open Innovation in Research, LEO Pharma